Incyte Corporation — Biotechnology. Scored on the same transparent 7-signal model behind the daily rankings.
★
INCY
Incyte Corporation · Biotechnology
FCF$1.4bC+
Rev+21.2%A-
D/E0.01A
P/E16.7xA-
PEG11.87D
73.9Score
$118.52$23.7B
1Y Target$111.45Analyst consensus · 22 analysts
5Y Target$163.18Compound horizon
10Y Target$242.07Long-dated conviction
FCF$1.4bTTM · 03/26C+
FCF $1.4b — respectable but not differentiating · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+21.2%TTM YoYA-
Revenue +21.2% — strong growth, well above S&P median (~7%)
D/E0.01A
D/E 0.01 — least levered decile in Healthcare (≈10th pctile)
P/E16.7xA-
P/E 16.7 — cheaper than most Healthcare peers (≈25th pctile)
PEG11.87D
PEG 11.87 — very expensive; pricing in best-case scenarios
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 73.9
Quality0.83
Growth0.97
Value0.50
Why this score
Diluting shareholders
Entry · Margin of safety
52-week rangeNear 52-week high
0% off the 12-month high
vs DCF fair value36% belowest. fair value ~$185
Quality signals · context only
Gross profitability68% · Agross profit ÷ total assets (Novy-Marx)
ROIC21.7% · Areturn on invested capital — not score-weighted
Why now
Biotechnology · market cap $23.7b. Trading near 52-week high of $118.97 — momentum setup, limited technical margin of safety. Revenue growing +21%, comfortably above the S&P median. 22 sell-side analysts rate this a Buy with a mean 1-yr target of $111.45 (implying -6% upside).
Moat
Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 25% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 99% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Reimbursement risk — even an approved drug can fail commercially if payors don't reimburse; pricing pressure from Medicare and large PBMs has been accelerating since 2024.
Horizon
1-3 yr $111.45 (22-analyst consensus) — fundamentals + valuation re-rating. 5 yr $163.18 at ~7% CAGR — compounding case rests on the competitive position widening. 10 yr $242.07 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · INCY
$
%
%
Shares to buy
16
Position size
$1,896
3.8% of portfolio
Stop price
$88.89
25% below $118.52
$ at risk if stopped
$474.08
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Incyte Corporation (INCY): score, valuation & FAQ
Incyte Corporation (INCY) is a Biotechnology company that scores 73.9 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are D/E (A), Rev (A-) and P/E (A-), while PEG (D) rate weaker. On valuation, INCY sits about 36% below our discounted-cash-flow fair value (a margin of safety).
Is INCY a good stock to buy?
Bull Rankings scores INCY 73.9 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by D/E (A), Rev (A-) and P/E (A-). A score is a quantitative screen of Incyte Corporation's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does INCY score 73.9 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). INCY earns its highest marks on D/E (A), Rev (A-) and P/E (A-), and is held back by PEG (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is INCY overvalued or undervalued?
Based on $118.52, INCY sits about 36% below our discounted-cash-flow fair value (a margin of safety). It trades at a 16.7x× P/E (graded A-). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in INCY?
Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Reimbursement risk — even an approved drug can fail commercially if payors don't reimburse; pricing pressure from Medicare and large PBMs has been accelerating since 2024.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.